

1/Flw
STO/SB/92 (09-04)Approved for use through 07/31/2006. OMB 0561-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**Certificate of Mailing under 37 CFR 1.8**

Applicant(s): Han et al.


Docket no. 95981

Application No. 10/566,532	Filing Date: January 31, 2006	Examiner: TBA	Customer No. 24628	Group Art Unit: TBA
Invention: High-Throughput Screening Method for Integrin Antagonist and New Peptide Screened Therefrom				

I hereby certify that this Supplemental Information Disclosure Statement is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on May 15, 2006.

(Date)

Eric D. Cohen, Registration No. 38,110
(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement; Supplemental PTO Form 1449, 1 "Foreign Patent" document, 9 "Other" documents and a return receipt postcard



Docket: 95981

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: HAN et al.

Group Art Unit: TBA

Serial No.: 10/566,532

Examiner: TBA

For: High-Throughput Screening Method for
Integrin Antagonist and New Peptide
Screened Therefrom

Filed: January 31, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

- ☒ 1 Pursuant to 37 CFR 1.97(b)
[within 3 months of filing or prior to 1st Office Action]
- ☐ 2 Certification Pursuant to 37 CFR 1.97(c)
[before Final Office Action or Allowance]
- ☐ 3 Fee Payment Pursuant to 37 CFR 1.97(c)
[before Final Office Action or Allowance]
- ☐ 4 Petition, Certification & Petition Fee Payment Pursuant to 37 CFR 1.97(d)
[before issue fee payment]

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SIR:

The following are submitted in the above identified application in compliance with 37 CFR 1.97 & 1.98:

- ☒ 5 A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 6 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 7 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ 8 The required certification made in item 11 below; or
- ☐ 9 The \$180.00 fee specified in 37 CFR § 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
- ☐ 10 37 CFR 1.97(d): [before issue fee payment]; and
- a) This is a petition for consideration of the subject Information Disclosure Statement. The petition fee (\$180.00) required by 37 CFR 1.17(i)(I) is authorized in item 14 below. (Direct this letter to: "Attention PETITIONS EXAMINER" and if applicable include batch locator information: e.g. "Allowed Files, Batch _____, Date of Allowance _____"), and

b) The required Certification is stated in item 11 below.

☐ 11 Certification

☐ 12 Each item of information in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or


☐ 13 No item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this document after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Statement.

☒ 14 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement to Deposit Account No. 23-0920. An original and one (1) copy of this document are enclosed.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references or to whether the references are considered "analogous art." This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or 103. This Information Disclosure Statement shall not be construed as an admission that the statement or cited references are, or are considered to be, material to the patentability under 37 C.F.R. Section 1.97(h).

Respectfully submitted,

WELSH & KATZ, LTD.


Eric D. Cohen
Reg. No. 38,110


WELSH & KATZ, LTD.
120 South Riverside Plaza
22nd Floor
Chicago, IL 60606
(312) 655-1500

May 15, 2006

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on this date:

May 15, 2006
Date


Eric D. Cohen, Esq.
Registration No. 38,110
Attorney for Applicants



Form PTO-1449 (Rev. 8-88)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 95981		Serial No. 10/566,532		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Han et al.				
				Filing Date January 31, 2006		Group No. TBA		
U.S. PATENT DOCUMENTS								
Examiner Initial*		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		10-2004-0007115	01.24.04	KR				X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		DUBREE, Nathan J.P. et al., "Selective $\alpha 4\beta 7$ Integrin Antagonists and Their Potential as Anti-inflammatory Agents", <u>J. Med. Chem.</u> , vol. 45:3451-3457 (8/2002)						
		HESSEL, Birgit et al., "Primary Structure of Human Fibrinogen and Fibrin, Structural Studies on NH ₂ -terminal Part of B β Chain", <u>Eur. J. Biochem.</u> 98, 521-534 (1979)						
		KOIVUNEN, Erkki et al., "Inhibition of β_2 Integrin-mediated Leukocyte Cell Adhesion by Leucine-Leucine-Glycine Motif-containing Peptides", <u>The Journal of Cell Biology</u> , vol.: 153:905-916 (5/28/2001)						
		KORNBLIHTT, Alberto R. et al., "Human Fibronectin: Cell Specific Alternative mRNA splicing Generates Polypeptide Chains Differing in the Number of Internal Repeats", <u>Nucleic Acids Research</u> , vol.12(14): 5853-68; (07.25.1984)						
		LEE, Yoonsuk et al., "ProteoChip: A Highly Sensitive Protein Microarray Prepared by a Novel Method of Protein Immobilization for Application of Protein-protein Interaction Studies", <u>Proteomics</u> 3:2289-2304 (2003)						
		SOININEN, Raija, et al., "Complete Primary Structure of the α_1 -Chain of Human Basement Membrane (type IV) collagen", <u>FEBS Letters</u> , vol. 225 (1,2):188-194 (1987)						
		SUZUKI, Shintaro et al., "Complete Amino Acid Sequence of Human Vitronectin Deduced from cDNA. Similarity of Cell Attachment Sites in Vitronectin and Fibronectin", <u>The EMBO Journal</u> , vol. 4(10):2519-2524, (1985)						
		TARUI, Takehiko et al., "Plasmin-induced Migration of Endothelial Cells, A Potential Target for the Anti-Angiogenic Action of Angiostatin", <u>The Journal of Biological Chemistry</u> , vol. 277(37):33564-33570 (2002)						
		TITANI, Koiti et al., "Amino Acid Sequence of Human von Willebrand Factor", <u>Biochemistry</u> , vol. 25: 3171-3184 (1986)						
Examiner				Date Considered				
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								